Search results
BioNTech says 90% of 2024 revenues will accrue at end of year
WSAU Wausau· 16 hours agoFRANKFURT (Reuters) - Germany's BioNTech, whose COVID-19 vaccine in partnership with Pfizer was...
Earnings call: Pfizer raises 2024 EPS outlook despite revenue decline By Investing.com
Investing.com· 5 days agoDespite a 19% decline in total company revenues to $14.9 billion, primarily due to the reduced...
Pfizer Jumps On 'Massive' First-Quarter Upside Thanks To Paxlovid Surprise
Investor's Business Daily· 5 days agoThat was partly due to a one-time $771 million infusion after the U.S. government returned 5.1...
Pfizer Stock Rises as Outlook Rises After Earnings Beat
Barrons.com· 6 days agoPfizer bumped up its earnings guidance on Wednesday while reporting better financial results than...
Why Pfizer Stock Blasted More Than 6% Higher Today
Motley Fool via Yahoo Finance· 5 days agoThe Covid effect not as damaging as feared For its first quarter, Pfizer reported before market open, the pharmaceutical giant took in just under $14.9...
Pfizer Inc (PFE) Q1 2024 Earnings Call Transcript Highlights: Navigating Post-COVID Challenges ...
GuruFocus.com via Yahoo Finance· 5 days agoPfizer Inc (NYSE:PFE) is navigating challenges in the post-COVID market, which continues to affect its financial performance. The company's gross margin ...
Pfizer Stock Is Near An 11-Year Low — But Is It A Buy On This 'Massive' Upside?
Investor's Business Daily· 5 days agoDuring the March quarter, the U...projection. The company also raised its sales outlook for the...
BioNTech says 90% of 2024 revenues will accrue at end of year
Reuters· 16 hours ago, opens new tab was widely used during the pandemic, said on Monday that almost all of its expected...
Pfizer (PFE) Q1 Earnings & Sales Top, EPS Guidance Raised
Zacks via Yahoo Finance· 5 days agoThe revenue decline, as expected, was due to a steep drop in revenues from its COVID-19 products,...
Moderna’s sales from its only product, the COVID-19 vaccine, fell 91% from last year
AOL· 4 days agoThe dark days of the pandemic are finally in the past for most of us—and that seems to be reflected in the earnings for Moderna, whose revenue is dependent on sales of its COVID< ...